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THESIS ABSTRACT: 
From Lost to Found: The Silent Transfer of Patients on Antiretroviral 
Therapy in Khayelitsha, South Africa 
Claudine Hennessey, BScN; Andrew Boulle, PhD; Kathryn Stinson, PhD 
Incorrect classification of silent transfer (STF) patients as lost to follow-up (LTF) 
negatively impacts accurate assessment of retention in care for antiretroviral (ART) 
programmes. Understanding reasons why patients STF and what proportion of LTF 
patients constitute this silent transfer phenomenon is necessary to ensure patient 
continuity of care. We attempted to identify STF patients using the routine 
government electronic monitoring systems. Furthermore, we sought to identify 
potential reasons for the STF phenomenon through patient surveys and healthcare 
provider interviews, in order to guide policy and improve programmatic outcomes.  
In this mixed methods approach, we selected patients identified as LTF between 
2008-2012 in three health facilities from Khayelitsha, Western Cape. Identified 
patients were subsequently searched for using a combined provincial patient data 
set. Once consent was obtained, sampling of patients and healthcare providers, 
using convenience and snowballing methods respectively, were selected for 
participation. 
Ninety percent of patients believe it necessary to inform facility staff of the intent to 
transfer, 56% of patients interviewed cited fear of negative attitudes from staff 
regarding transfer request (65%), family situations (30%), and long waiting times 
(11%) as contributing factors to silently transferring care between facilities. 
Healthcare providers cited stigma, family obligations and/or support, and migration to 
the Eastern Cape as main reasons for patients transferring. Healthcare providers 
cited incomplete or lack of transfer documentation as the biggest barrier to timeous 
treatment of the transfer patient. 
Incorrect reporting of patients as lost to follow-up negatively affects the treatment 
programmes retention in care. Negative staff attitudes and poor operational services 
prevent patients informing staff of transfer intent. The treatment programme must 
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adapt current transfer policies in order to facilitate the transfer process for all 
patients, including those experiencing emergencies and life events. Linked electronic 
patient monitoring systems will improve accurate retention in care reporting and 
improve fluidity of transferring of patients between health services. 
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Part A: Protocol 
 Figure 1: ART patient classification for monitoring 
 
 Figure 1: Map of Western Cape Cape Town Metro District Health Services 
and Sub-District Health Areas 
 
 Table 1: Variables for Qualitative and Quantitative Data 
Variables Table 
  Description Data Source Name of Variable Type 
Baseline Demographics eKapa Current Age Numerical 
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Sex Categorical 
ART information 
Age at ART Start Categorical 
Outcome   Categorical 
Name of facility Categorical 
Follow-up 
ART information 
Provincial data 
set 
Name of STF facility Categorical 
Location of clinic Categorical 
Method into ART  Categorical 
Prior ART Categorical 
Number of transfers Numerical 
Healthcare provider 
information 
Health provider 
in-depth semi 
structured 
interviews 
Type of health provider Categorical 
Duration of employment Numerical 
Duration of employment in ART service Numerical 
Type of transfer patients Thematic 
How do you assess transfers who arrive 
without documentation? 
Thematic 
Clinical requirement pertaining to transfer Thematic 
Reasons for transfer Thematic 
Health providers perceptions of transfer Thematic 
Health providers perceptions of silent transfer Thematic 
Health providers perception of transfer 
limitations 
Thematic 
Health providers reasons for transfer 
limitation 
Thematic 
Managing STF or transfer patients Thematic 
Health providers policy and programmatic 
classifications 
Thematic 
Patient Information Patient Survey 
Duration on ART Numerical 
ART status Categorical 
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Distance from home to health facility Numerical 
Time to travel Numerical 
Type of transport Categorical 
Cost of transport Numerical 
Information regarding transfer rules Categorical 
Type of information Categorical 
Care Satisfaction Categorical 
Patient Care improvement suggestions Categorical 
Moving clinic notification Categorical 
Reasons for not informing transfer Categorical 
Reasons for transferring Categorical 
Medication interruption Categorical 
Duration without treatment Numerical 
 
Part B: Literature Review 
 Figure One. 2: WHO Patient Treatment Cascade (1,17) 
 
 
Part C: Article 
 Figure 1: Patient classification at time of entry into health facility 
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 Table 1: Patient Characteristics of Silent Transfer Patients and Non Silent 
Transfers 
Table 1: Patient Characteristics of Silent Transfer Patients vs Non Silent transfers 
Characteristic Adults (≥15 yrs), N=4166 
 
STF patients 
n=1521 
Non STF patients 
n=2645 
Age at ART Start (yrs), median (IQR) 31 (27-36) 33 (28-40) 
Age Categories, n (%) 
15-24 yrs 227 (15) 258 (10) 
25-34 yrs  792 (52) 1209 (46) 
35-44 yrs  373 (25) 777 (29) 
45+ yrs  129  (9) 401 (15) 
Gender, n (%)   
Women 1027 (68) 1533 (58) 
25-34 yrs  561 (55) 770 (50) 
35-44 yrs  197 (19) 380 (25) 
Men 494 (32) 1112 (42) 
25-34 yrs  231 (47) 439 (39) 
35-44 yrs  176 (36) 397 (36) 
Number of times transferred, n (%)  
Once 1283 (84) 
  
Twice 196 (13) 
  
2-5 times 42 (3) 
  
Location of Silent Transfer within Western Cape Province, n (%)  
Cape Town MDHS** District 1380 (91)   
Khayelitsha Sub-district (within MDHS District) 968 (70)   
16 
Outside of Metro 141 (9)   
Recorded ‘Method into ART’ status at transfer in (TFI) facility*, n (%) 
Incorrectly recorded as ‘New’ at TFI facility 1097 (72)   
Of these patients, incorrectly captured as ‘ART Naïve’, meaning no 
prior ART experience 
1039 (95) 
  
Correctly captured as TFI at transfer facility 424 (28)   
**Metro District Health Service;  
*Programmatic classification used to determine if a patient is new to treatment or has come from another facility. ‘New’ 
implies that a patient has not been on triple therapy before their arrival at ART enrolment facility.  
*Programmatic classification used to determine if a patient is new to treatment or has come from another facility. ‘New’ 
implies that a patient has not been on triple therapy before their arrival at ART enrolment facility. ‘Naïve’ refers to a 
patient never having exposure to ART prior to their first triple therapy ART start date.  
^Patients who were not linked, who may have been true LTF or STF care outside of the Western Cape.  
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INTRODUCTION: 
In 2012, there were an estimated 35.5 million people living with HIV with 25 million of 
those living in Sub Saharan Africa (1). In South Africa, over 6.1 million people are 
living with HIV (2) with just over 2 million having ever been initiated on antiretroviral 
therapy (ART). There is global consensus that patients who remain adherent on ART 
can virally supress the disease, reduce the risk of transmission to others, and live 
their lives with minimal interruption to activities of daily living (2–4). However, a weak 
and overburdened healthcare system can negatively impact on patient outcomes, by 
influencing a patients ability to access and remain on treatment (5). 
Scale up of Antiretroviral Therapy (ART) Services in South Africa: 
The rapid scale-up of the ART program in South Africa over the past decade has 
enabled almost 2 million HIV-positive patients to initiate lifesaving ART (6). There 
have been significant advances within the South African HIV treatment program 
including changes to the enrolment criteria, improvements in regimens and nurse-
driven initiations and management of patients. Specific programmatic targets set 
forth by the National Strategic Plan for HIV/AIDS have contributed to the rapid 
expansion and scale-up of the ART program (2,7,8). 
In the Western Cape, the rapid scale-up of ART has enabled over 100,000 patients 
to initiate treatment between 2001 and 2012 (9), with over 30,000 patients having 
initiated in the township of Khayelitsha (10). Khayelitsha not only is one of  the 
largest cohorts of patients on ART, it is also one of the oldest in South Africa, with 
ART being made available in April 2000 through the collaboration with Médecins 
Sans Frontières (MSF) and the Western Cape Provincial Department of Health 
(3,11).  
The burgeoning patient population due to scale-up within a constrained health 
system has necessitated the need for new and innovative ways to keep patients on 
ART. This has led to a  shift in program strategy from concentrating on scale- up and 
roll out, to optimizing models of adherence and retention in care (12–14) whilst 
developing strategies to decongest the overburdened health facilities. Although 
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several innovations are showing positive results, still more must be done to ensure 
that patients, who initiate ART, remain on ART for life. 
Health System Impact on the rapid expansion of the ART programme: 
The rapid expansion and scale-up of the ART program is a challenge in itself, 
frequently with weak and insufficient health services contributing suboptimal 
implementation. Linkage and referral of patients between services is often poor; 
patient monitoring systems are not operationally prioritized, and human resources 
are not sufficiently capacitated to actively follow up those patients defaulting 
treatment, resulting in an increasing number of patients being lost to care (15,16). 
At the inception of the HIV treatment program in South Africa, patient to clinician 
ratios enabled patients to receive intensive, individualized and focused care resulting 
in few patients defaulting treatment and subsequently becoming lost to the program 
(4). However, over time, it has understandably been challenging for healthcare 
providers to provide the same individualized care for such a large group of patients 
as changes in ART eligibility criteria have enabled more people to begin treatment 
and the long-term service burden of patients on ART has increased (8). This is also 
compounded by an ever-increasing mobile population. The mobile population 
includes patients who move for a variety of reasons between health facilities. This 
movement can be from one facility to another within a sub-district or district, 
provincial or country health management structure that move between facilities, or 
‘silently’ transfer their care. Some evidence points to more common reasons for 
movement being associated with socioeconomic factors, for instance transport, 
financial and family responsibility challenges as found in a study in Uganda (17). 
Health facilities are struggling to cope with the surge in patient numbers, which has 
led to operational difficulties in monitoring defaulting patients who have become LTF, 
including identifying those who have potentially silently transferred, given that this 
activity is time consuming and costly on a large scale. This has contributed to the 
increase in defaulting patients documented as LTF (15). In a study conducted in 4 
rural health facilities in Malawi, 7% of patients considered LTF had in fact silently 
transferred their care to another health facility (16). As the South African ART 
program matures and continues to grow, it is important to learn more about the silent 
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transfer and and the current transfer processes, and adapt those policies in order to 
provide the optimal care for this cadre of patients. 
Monitoring of ART Services- the 3 tier approach: 
The monitoring of the ART services in South Africa has undergone expansion and 
changes in response to scale-up since its introduction in 2001. The Western Cape 
Department of Health was one of the first government health programmes to 
implement longitudinal monitoring of patients initiated on ART and in 2011 the 
National Department of Health adopted the 3 tier monitoring strategy (18). The 3 tier 
monitoring system monitors the clinical and programmatic outcomes of the ART 
programme (19). Through the use of cohort monitoring the ART programme has 
been used to guide policy and programmatic changes. The HIV Programme has 
primarily focussed on retention in care and the monitoring of health outcomes 
(defined below) in order to guide programmatic interventions. 
ART programme outcome definitions: 
In the South African ART programme, there are four definitions used to classify a 
patients ART treatment status: Remaining in Care (RIC) and Outcomes of Died 
(RIP), Transfer/Moved-out (TFO) and Lost to follow-up (LTF). In addition there are 
two classifications of patients used when commencing ART at a health facility. New 
patient (New) refers to those patients who are beginning ART for the first time at the 
time of ART initiation (meaning they have not been on lifelong ART prior to 
commencing), or those patients who have been on ART previously but who have 
defaulted treatment and are restarting; Transfer In (TFI) refers to those patients who 
are coming from another ART facility, already on treatment and are continuing their 
care at a new facility without interruption. These programmatic definitions follow 
those guidelines established by the World Health Organization (WHO) and adopted 
by the South African National Department of Health (NDoH) in monitoring the ART 
programme (19–22). 
Lost to Follow-up (LTF): 
According to the SA national M&E guidelines which follow the WHO Monitoring and 
Evaluation Guidelines patients are defined as unconfirmed loss to follow up when 
26 
they have not accessed a health facility in 3 months, and/or have gone without drugs 
in hand for > 90 days (21). Patients are described as confirmed loss to follow if they 
are confirmed LTF through active attempts at tracing, through the use of either home 
visits or telephonic follow up, usually conducted by community health workers 
(CCWs) or other designated healthcare workers. In this study the term LTF will be 
generalized to include confirmed and unconfirmed LTF as documentation of 
confirmed loss to follow up is difficult to ascertain given the constraints of the 
healthcare system. 
Silent Transfers (STF): 
Although there are defined criteria for classifying a transfer out (TFO) patient, for the 
purpose of this study we will be looking at those patients considered a LTF who are 
actually alive and in care at another facility, hence making them a ‘silent transfer’ and 
not a true LTF. The definition for a silent transfer within the context of this research 
study is a patient who leaves clinical care at one health facility without notification to 
the departing facility of their intended transfer, and arrives at a new facility to 
continue their care  
This cohort of patients will include patients who are considered LTF at their previous 
facility, and may be considered restarting patients at their new facilities depending on 
how long they have been without treatment.  
Figure 1 indicates how patients who move between facilities are to be captured into 
the monitoring systems. Health providers are responsible for identifying patients as 
New or TFI patients depending on the findings during consultation with their patient. 
A New patient is defined as any patient who is initiating triple therapy for the first 
time. Prior ART refers to those patients who have been on treatment before for 
greater than 30 days. Historically and prior to the provision of ART being made 
available to all patients, many patients were receiving ART in either a private sector 
or as part of a research trial. In order to accurately account for a patients experience 
on ART the term Prior ART was used to differentiate those patients from patients 
who were Naïve to treatment. In the monthly data, only patients who are New, Naïve 
are included in the ART initiation numbers for a facility; under or over reporting of 
New initiations can have negative implications for the ART programme.  
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Figure 1: Patient flow between ART services 
 
Justification of Research: 
LTF has become one of the most important outcomes to identify ART programme 
effectiveness (23,24). It is known that patients move between health services, 
sometimes requesting official transfers between facilities or sometimes silently 
transferring (STF) to other health facilities, although neither of these movements are 
monitored, managed or well documented (16,25). This may result in an inflation of 
LTF proportions. The constraints of the healthcare system in tracing patients can 
contribute to an over-inflated reporting of LTF; as patients who are deemed LTF may 
be on treatment in other health facilities, however, the capacity of monitoring 
systems to identify them as such are not currently in place. 
In order to ensure continuity of patient care it is essential that the HIV programme 
explore the relationship between LTF patients and STF. Could it be that improved 
monitoring of transfer patients may reduce the overall number of patients identified 
as LTF within the ART programme? 
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Problem Statement: 
As more patients become eligible for life long ART and treatment duration increases, 
it is likely that services will experience more patients becoming lost to clinical care or 
LTF. It is imperative to identify whether patients considered LTF are in care at 
another facility. Understanding this STF population will improve and ensure effective 
management of this patient within the ART programme.  
Aim: 
The aim of this research is to identify and describe the characteristics of the STF 
patient in three primary healthcare ART services in Khayelitsha in order to inform 
ongoing clinical care and programmatic management of patients accessing ART 
services over time. 
Objectives: 
The objectives of the proposed study are as follows: 
1. To determine how many patients in the three ART services who are identified 
as LTF are STFs.  
2. To describe the characteristics of these patients including the geographical 
location of STF facilities.  
3. To describe reasons why patients STF between services. 
4. To identify the perceptions and attitudes of health providers towards STFs, in 
order to identify any potential barriers which could impact on the continuity of 
care.  
Research Questions: 
1. What proportion of patients documented with a LTF outcome are STFs? 
2. What are the patient characteristics of a STF patient? 
3. What is the geographical context for patients between ‘lost’ and ‘found’ 
facility? 
4. What are patient reasons for STF? 
5. What are the perceptions of clinical staff regarding the overall and STF 
transfer process? 
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Methods: 
Study design: 
The study will apply a mixed method study design using retrospective cohort data, 
and patient and health provider’s interviews. 
Population:  
The study population comprises all adult patients (>15 years of age) ever initiated on 
ART with an outcome of LTF in the health sub-district of Khayelitsha. 
Study Sample: 
The study sample includes adults initiated on ART between January 1st 2001 and 
September 30th 2012 with a documented outcome of lost to follow-up (LTF) between 
January 1st 2008 and December 31st 2012 within three identified provincial health 
facilities within Khayelitsha. 
Catchment Area: 
Located in the Cape Town Municipality of the Western Cape, the township of 
Khayelitsha is the second largest townships in all of South Africa with a population of 
over 0.5 million mostly African Xhosa speaking residents. Created during apartheid 
and officially established in 1983 to resettle African residents, Khayelitsha consists of 
over 22 proximately informal settlements and is plagued by high crime and 
unemployment (Affordable land and housing data centre, n.d). In terms of health, 
antenatal HIV prevalence was measured at 31.1% in 2008 with an HIV/TB co 
infection rate of close to 70% (26). It also has one of the oldest and largest cohort of 
patients on ART, due in large part to the support of MSF working in collaboration 
with the City of Cape Town and the Provincial Government of the Western Cape 
(11). 
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Figure 3: Map of Western Cape Cape Town Metro District Health Services and Sub-District Health Areas 
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Sampling Methods: 
Sample Size: 
Quantitative Data: 
The proposed sample (n=4166) is any adult (≥18 years of age) who ever initiated 
ART in one of 3 Primary Healthcare (PHC) facilities in the sub-district of Khayelitsha 
(Michael Mapongwana, Nolungile and Ubuntu) who had a recorded outcome of LTF 
between January 1st 2008 and December 31st 2012. 
Inclusion criteria: 
1. Adult patients who initiated ART at Michael Mapongwana, Nolungile or Site B 
(Ubuntu) facilities. 
2. Patients with an outcome of LTF from January 1st 2008 – September 30th 
2012. 
Exclusion Criteria: 
1. Patients considered LTF without an ART start date will be excluded from the 
study, as these patients will most likely be patients who have defaulted having 
never started treatment. 
2. Patients who were considered a TFI, meaning their ART initiation occurred at 
another health facility. 
3. Patients less than 15 years of age at time of ART initiation. 
Qualitative Data: 
A convenience sample of 30 patients and 5 health providers from different ranks in 
the health service1 will be selected for a survey and in-depth interviews respectively. 
Since the purpose of interviewing patients and health providers is to understand 
                                            
1 Although doctors had initially been considered for the inclusion criteria, interviews were conducted with nurses only, due to the clinical 
referral process. Nurses were more suited to answer questions regarding transfer patients as doctors were allocated to consult patients who 
had already been assessed by nurses. 
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potential reasons for and perceptions of silent transfer, this sampling strategy should 
be adequate to provide sufficient thematic data of a formative nature for the study. 
Inclusion Criteria (Patient Survey): 
1. Adult (over the age of 18 for consenting purposes) patients on ART  
2. Patients on ART at Michael Mapongwana, Nolungile, and Site B (Ubuntu) 
CHCs. 
Inclusion Criteria (Healthcare provider in-depth semi-structured interview): 
1. ART health provider (nurse or doctor) 
2. ART health provider (nurse or doctor) working at Michael Mapongwana, 
Nolungile, Site B (Ubuntu). 
Data Collection: 
Quantitative Data: 
To identify those patients with an outcome of LTF, data from the routine HIV 
monitoring system used by the Provincial Government of the Western Cape and 
National Department of Health will be extracted. In order to determine whether 
patients identified as LTF, the provincial HIV monitoring system will be used to 
search for any evidence of presence at another facility in the Western Cape after the 
period of documented LTF. Patient identifiers, including Patient Folder Number, 
Name, Sex, Date of Birth, and South African/Foreign ID number, will be used to 
ascertain whether transfer to another facility occurred. Given the data available, 
searches will be limited to movement within the Western Cape Province, however, 
effort will be made to record any indication of migration outside of the province where 
possible. 
Identified patients will be described in terms of age, gender, number of transfers and, 
location of STF facility, prior ART and previous ART status.  
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Qualitative data: 
A survey of patients and semi-structured in-depth interviews with health providers 
will be conducted at the three Khayelitsha provincial health facilities in order to 
explore the health system barriers facing silent transfers and patient reasons for 
silently transferring.  
Given the resource constraints of the study, patients attending the three ART 
services will be selected to describe their potential reasons for transfer. The survey 
will be given to patients waiting in the ART reception area(s) of the health facility and 
the health provider questionnaire will be given to health providers working in one of 
the three health facilities. The recruitment of patient participants and the selection of 
HCPs will be done using convenience-sampling methods. A research assistant will 
provide participants with a written explanation of the study and informed consent will 
be obtained before administration of the study instrument. No names will be 
recorded on the questionnaire, and all of the participants will be assigned a number 
for identification purposes (see Ethical considerations below). The study lead or 
research assistant will be on hand to administer the survey and answer any 
questions that arise.  
Patient surveys will be translated from English into Xhosa, the predominant 
languages spoken in Khayelitsha. The surveys will be back translated as a measure 
of quality control in order to ensure that conceptual equivalence is maintained, rather 
than merely being a direct translation. Health provider questionnaires will only be 
offered in English, given that this is an officially recognised spoken language within 
the services. 
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Instruments and data sources: 
Quantitative data: 
Retrospective cohort data will be assembled from the Western Cape Government 
provincial ART electronic monitoring system (eKapa), the combined Western Cape 
Government provincial ART data set that contains a combination of data from 
several patient information systems (TIER.Net, Prehmis, eKapa, NHLS). 
Qualitative data: 
Qualitative data will be assembled from patient surveys and from semi-structured in-
depth health provider interviews. 
Variables: 
Data collected will yield the following variables: 
Table 1 Variables Table for Qualitative and Quantitative Data 
Variables Table 
  Description Data Source Name of Variable Type 
Baseline 
Demographics 
eKapa 
Current Age Numerical 
Sex Categorical 
ART information 
Age at ART Start Categorical 
Outcome   Categorical 
Name of facility Categorical 
Follow-up ART information 
Provincial data 
set 
Name of STF facility Categorical 
Location of clinic Categorical 
Method into ART  Categorical 
Prior ART Categorical 
Number of transfers Numerical 
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health provider 
information 
Health provider 
in-depth semi 
structured 
interviews 
Type of health provider Categorical 
Duration of employment Numerical 
Duration of employment in ART service Numerical 
Type of transfer patients Thematic 
How do you assess transfers who arrive 
without documentation? 
Thematic 
Clinical requirement pertaining to transfer Thematic 
Reasons for transfer Thematic 
Health providers perceptions of transfer Thematic 
Health providers perceptions of silent transfer Thematic 
Health providers perception of transfer 
limitations 
Thematic 
Health providers reasons for transfer 
limitation 
Thematic 
Managing STF or transfer patients Thematic 
Health providers policy and programmatic 
classifications 
Thematic 
Patient Information Patient Survey 
Duration on ART Numerical 
ART status Categorical 
Distance from home to health facility Numerical 
Time to travel Numerical 
Type of transport Categorical 
Cost of transport Numerical 
Information regarding transfer rules Categorical 
Type of information Categorical 
Care Satisfaction Categorical 
Patient Care improvement suggestions Categorical 
Moving clinic notification Categorical 
Reasons for not informing transfer Categorical 
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Reasons for transferring Categorical 
Medication interruption Categorical 
Duration without treatment Numerical 
 
Data Management: 
Quantitative: 
The researcher currently has access to the provincial monitoring system (eKapa), 
has been provided with a user name and password, and is monitored through the 
Western Cape Health Information Management Programme as part of Protocol 
395/2005 – ‘Enhanced Routine Surveillance of Patient in HIV Care in Khayelitsha’. 
Linkage data will be sought from the routine system and analysed using Stata 12 
(StataCorp, College Station, USA). 
Qualitative: 
Completed surveys will be kept in a sealed envelope for transport between the 
facility and the study lead’s office. Once the envelopes arrive, they will be captured 
into an excel spreadsheet with the date and the number of the survey or interview 
form. No named data will be collected on the forms, thereby ensuring participant 
privacy and confidentiality. Data from the surveys and interviews will be translated, 
transcribed, and captured verbatim into a word processing programme and 
thematically categorized using Atlas.ti.  
Data analysis: 
Quantitative Analysis: 
In order to analyse the data generated by the proposed study, univariate analysis will 
be conducted.  
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To begin with, exploratory data analysis will be performed in order to detect and 
clean errors or unexpected patterns within the data. Information on any participants 
with missing or incorrect data will be re-examined and entered if possible, or 
otherwise these observations will be removed if deemed necessary. 
Descriptive statistics will be compiled using the socio-demographic and patient 
characteristics data as shown in Table 1. The proportion of LTF patients who are 
STF will be calculated and confidence intervals will be calculated using this 
proportion in order to estimate the population proportion of silent transfers. This will 
allow an extrapolation of the STF prevalence within the sample to an estimated 
prevalence at the population level. 
The proportions of outcomes at last visit will be described along with sex, age, time 
to transfer and number of transfers. Chi squared test will be used to test an 
association between categorical variables.  
Qualitative Analysis: 
The data will be sorted using a thematic classification approach. The results will be 
examined for common themes that are repeated in the results and will be used to 
analyse the findings. 
Data from the surveys and in-depth interviews and the cohort data will enable data 
triangulation, thus strengthening the evidence and generalizability of the study. 
Pilot Study: 
A pilot study will be conducted prior to beginning of the qualitative data collection. 
The main objectives of the pilot study are to test: 
1. Sampling Strategy 
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2. The data collection and measurement methods 
3. The patient and health provider survey 
In order to conduct the qualitative study, a research assistant will be trained on the 
use of the survey, maintaining participant confidentiality, data capturing and 
recording. The pilot study will involve administering the survey to three randomly 
selected patients and health providers from a similarly defined primary healthcare 
facility. The aim of the pilot study is also to assess the feasibility recruiting and 
completion of the survey. During the pilot study, the research assistant will record the 
length of time it takes to complete each survey, preferred survey language, 
challenges of the survey questions and other difficulties encountered. Through this 
process, it is hoped that any major issues will be highlighted. The pilot study will lead 
to the refinement of the questionnaire and sampling strategy prior to data collection. 
Ethics: 
The ethical principles which will be adhered to at all times during the study will be 
those stated in the Declaration of Helsinki, which was developed by the World 
Medical Association for medical research involving human participants (27). It will 
thus be ensured that the well-being of each individual participant takes precedence 
over all other interests. In addition, the proposed study will be guided by the ethical 
principles and guidelines set out in the Belmont Report, namely those of respect for 
persons, beneficence, and justice.  
Ethical Approval: 
Ethical approval to conduct the study forms part of an existing protocol ‘Enhanced 
routine surveillance of patients in HIV Care in Khayelitsha’ (HREC REF # 395/2005), 
approved through the Faculty of Health Sciences Human Research Ethics 
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Committee of the University of Cape Town and from the Western Cape Department 
of Health. The Principal Investigators are Drs’. Andrew Boulle and Eric Goemaere, 
with a team of collaborators from Khayelitsha stakeholders represented as co-
investigators.  
Ethical Considerations: 
Participants will be informed during the consent process that their participation is 
voluntary, that they have the right to refuse to participate or to suspend their 
participation in the course of the survey and that confidentiality will be protected at all 
times. They will be reassured that there will be no negative or positive consequences 
of participating or not participating in the study with regards to their clinical care –in 
the case of patients; nor work environment – in the case of health providers. 
Participants will be given full details of the need and aims of the study as well as all 
details regarding the methods, dissemination of results, and their role in the study. 
Participants will also be informed that the research is for the purpose of an academic 
study contributing to the researchers’ Masters in Public Health thesis and not as part 
of the researcher’s job with the Centre for Infectious Disease, Epidemiology, and 
Research at the University of Cape Town. Since Khayelitsha is a predominantly 
Xhosa speaking population, participants will be given the option to take the survey in 
Xhosa or English. All health provider surveys will be offered in English only, as 
English is the preferred documentation method within the Department of Health.  
The research assistant who has been recruited for this study is fluent in both English 
and Xhosa. The research assistant has worked in the clinical setting as a data clerk 
for several years and is aware of the programmatic and clinical terminology for the 
40 
HIV programme. This will allow for further probing of questions and themes, and 
more accurate responses to the patient survey, should the need arise.  
Confidentiality will be maintained as no named information will be collected from the 
survey and interviews. Identifying variables that will be collected include only 
designation and facility name, however facility identifiers will be coded using an 
identifier that only the principle research will have access to. All surveys and 
interviews and will be stored in a sealed envelope and placed in a lockable drawer, 
accessible only to the research team. 
All survey participants will be given the contact details of the researcher, the 
supervisor and primary investigator and the HREC should they have further queries 
or concerns. In addition, the contact details or the HREC will be documented on the 
consent form and each participant will be given a copy of the consent for their 
information. No participant will receive any form of monetary or in kind 
donation/incentive for participating. 
Patient information is considered confidential under the Batho Pele principles of 
health services. Information found in the routine data set may be above and beyond 
the researcher’s primary questions, however this information will not be copied or 
removed from the data set, In reviewing the routine data set there is a risk that 
information regarding patient clinical status such as non-clinically actioned 
unsuppressed viral loads. In this instance the information will be presented to the 
facility manager to ensure that the patient is recalled to the clinic in an appropriate 
and timely manner, and respect to the health providers privacy in the event of a 
required intervention and will be addressed following the ART clinical guidelines. 
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There will be no information collected in the patient monitoring system, or the patient 
and health providers’ survey process that will cause risk of divulging patient 
identifiers researcher conducting this study understands the Batho Pele Principles 
and Ethical implications to maintaining patient confidentiality. There is a risk that 
participants may be unclear about the role of the researcher in relation to her role as 
a technical advisor and project coordinator with CIDER, UCT. The researcher would 
like to reiterate that the research is for the purpose of an academic study, 
contributing to her Master’s thesis in Public Health, and not part of her professional 
portfolio with UCT. This will be made clear at the start of the interaction, to ensure 
that the participant is comfortable with being interviewed. 
By identifying the potential reasons why patients chose to silently transfer will 
improve patient management for this group. Improved management would include 
better follow up and identification of patients who have potentially silently transferred. 
It is also hoped that the findings will improved the documented transfer requests 
from patients, thereby reducing the potential number of patients who are inaccurately 
identified as LTF.  
By focusing on silent transfer patients, it is hoped that the research will inform the 
ART programme within but not limited to the Western Cape on how to appropriately 
identify the silent transfer, reduce the overall number of LTF patients, and help 
facilitate the process for patients requesting transfers to other facilities. 
Other potential benefits include enhanced monitoring of silent transfer patients, 
improvements to clinical care, operational management within the health facility and 
inform policy that would benefit both the patient the facility staff and the ART 
programme. 
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Dissemination of research findings: 
The proposed study will be submitted in partial fulfilment of the requirements for the 
Master of Public Health degree at the University of Cape Town. Findings from the 
study will be reported back to the Western Cape Department of Health HIV, AIDS, 
STI, TB Treatment Programme including, but not limited to the management 
structures for the Provincial and City of Cape Town departments of health, facility 
management, health providers, administrative staff and other stakeholders. 
Publishable articles based on the findings from the research will be submitted to 
relevant research journals and presented to key stakeholders.  
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Logistics: 
Budget: 
Budget for Proposed Study 
Item Cost per unit Number of units Total cost 
Field worker R60/hour 40 hours R3200 
Translation of surveys R60/hour 10 hours R600 
Mileage R3.16/km 35 visits to study sites 
(approximately 40km/visit) 
R4424 
Photocopying R0.30/page 1000 pages R300 
   R800 
Total   R9324 
 
Funding source: 
The funding for this study will be provided through the existing and approved 
research study – HREC REF # 395/2005 
Time frame: 
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Departmental and ethical 
approval 
x      
Pilot study   x       
Data collection     x X     
Data capturing      X     
Data analysis -     X     
Writing of manuscript    X x   
Submission of dissertation and 
dissemination of findings 
      x x 
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Literature Review: 
This thesis investigates patients within the antiretroviral therapy (ART) programme 
identified as lost to follow-up (LTF) who have self-referred or silently transferred 
(STF) their care to or from another health facility. We seek to identify and describe 
the characteristics of the STF patients in order to inform ongoing clinical care and 
programmatic management of patients accessing ART services over time. We 
further explore the perceptions and attitudes of health providers towards the STF 
patient in order to identify any barriers affecting the continuum of patient care and 
potential reasons why patients STF between health facilities.  
To inform this research, the objectives of the literature review are:  
1. To describe the scale-up of the ART programme within the South African 
context. 
2. To explore current research regarding LTF outcomes of patients and attempts 
to trace those patients within the ART programme, including the tracing of 
STF patients. 
3. To investigate the impact of migration and transferring of patients and their 
effect on the health services. 
Literature Search Strategy: 
PubMed and Google Scholar were searched and a manual search of reference lists 
from relevant articles using the search terms using the search terms HIV, 
antiretroviral treatment, Lost to follow-up (LTF), transfers, migration, self-referral, 
silent transfer (STF) and monitoring and evaluation. A general Google Scholar 
search for local and international reports such as the WHO and NDoH not cited on 
medical databases was also conducted. 
The search was restricted to English language publications and data reported from 
the African continent. Titles and abstracts of resulting articles were reviewed and 
references of included studies and existing reviews were searched. All publications 
available through July 1st 2015 were included in this review. Publications were 
included in the review if the population of interest included patients on ART where 
LTF, tracing, and self-referral was referenced. Articles that described the ART 
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programme within the context of the Primary Healthcare System and the 
relationships between HCPs, patients and the health system were also explored. 
Articles pertaining to pre-ART treatment, prevention of mother to child transmission 
(PMTCT), antenatal, and children were excluded from this review.  
Box 1: Search strategy term used 
Anti-retroviral treatment, retention in care, lost to follow-up, silent transfer, self-transfer, migration, 
monitoring and evaluation, programme guidelines, health provider/patient relationships.  
Introduction: 
In 2012, there were an estimated 35.5 million people living with HIV throughout the 
world, with 25 million of those living in Sub Saharan Africa (1). In South Africa, over 
6.1 million people live with HIV with just over 2 million initiated on (ART) (2). There is 
global consensus that patients who remain adherent on ART can virally supress the 
disease, reduce the risk of transmission to others, and live their lives with minimal 
interruption to activities of daily living (2–4). However, a weak and overburdened 
healthcare system can negatively impact on patient outcomes, by influencing their 
ability to access and remain on treatment (5,6). 
Scale up of Antiretroviral Therapy (ART) Services in South Africa: 
The rapid scale-up of the ART programme in South Africa over the past decade has 
enabled almost 2 million HIV-positive patients to initiate lifesaving ART (2,7). There 
have been significant advances within the South African HIV treatment programme 
including changes to the enrolment criteria, improvements in regimens and nurse-
driven initiations and management of patients. Specific programmatic targets set 
forth by the National Strategic Plan for HIV/AIDS have contributed to the rapid 
expansion and scale-up of the ART programme (2,5,8). 
In the Western Cape, the scale-up has enabled over 100,000 patients to initiate ART 
between 2001 and 2012, with over 30,000 patients having initiated in the township of 
Khayelitsha (9,10). Khayelitsha not only is one of  the largest cohorts of patients on 
ART, it is also one of the oldest in South Africa, with ART being made available in 
April 2000 through a collaboration with Médecins Sans Frontières (MSF) and the 
Western Cape Provincial Department of Health (3,4).  
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Since its inception, the ART treatment programme’s primary focus has been to test 
and initiate as many eligible patients as possible using the WHO clinical treatment 
guidelines (11). These guidelines have been adapted for the South African context to 
ensure optimal coverage of ART for all eligible patients (12).  
Eligibility for ART initiation has improved since ART was first introduced, with current 
South African National Department of Health guidelines now including initiation for 
adults with a CD4 cell count below 500 cells/mm³, adults with Hepatitis B infection, 
adults with tuberculosis (TB), HIV-positive partners in serodiscordant couples, HIV-
positive pregnant women and women within one year post-partum (13,14). Changes 
in ART guidelines over time has contributed to the reduction in death attributable to 
HIV, with more patients able to live healthy and productive lives (10,15,16). 
Testing, linkage to care and initiation of patients on ART are only a few of the 
components of the HIV treatment cascade (figure 1). Additional components include 
virological suppression, prevention of death and LTF, and retention and return to 
care (1,8). 
 
Fig. 4: Treatment Cascade (1,17) 
This review will focus on LTF, retention and return to care with a specific focus on 
self-referral or the STF of patients. 
The burgeoning patient population due to scale-up and guideline changes within a 
constrained health system has necessitated the need for new and innovative ways to 
51 
 
keep patients on ART. This has led to a  shift in programme strategy from 
concentrating on scale-up and roll-out, to developing strategies to decongest the 
overburdened health facilities whilst optimizing models of adherence and retention in 
care (18–20).  
Although the treatment guidelines have adapted to the clinical needs of the patients, 
little focus has been place on the development, implementation, and management of 
processes and policies for patients transferring between health facilities.  
Monitoring of ART programme: 
Success of the ART programme should not only be measured by those who initiate 
ART, but include those who remain on treatment (1,21). Globally the measurement 
of success of the ART programme is done via routine longitudinal-cohort monitoring 
of patient outcomes (10,22,23). The World Health Organisation ART programme 
defined outcomes include: Rest in Peace (RIP) for patients who have died, Lost to 
follow-up (LTF) for those who have are no longer in care, Transferred Out (TFO) for 
patients who have requested a transfer to another health facility, and Retention in 
Care (RIC) for those patients on ART treatment and in care at a health facility (24).  
LTF has become one of the most important outcomes to identify ART programme 
effectiveness (25,26), although the concept and definition of LTF is varied throughout 
the literature (25) with some studies considering a LTF after 4 weeks of missed 
appointments, and others using the WHO definition of ≥90 days drugs not in hand 
(22). LTF outcomes after one year on ART contributes to 20% of attrition within the 
ART programme, with the risk of LTF increasing as duration on ART increases 
(22,26,27). Retention in care at 24 months is 70% with the proportion of LTF patients 
having transferred to other facilities varying considerably between 7% and 56% (28–
30).  
Patients who STF add to the increase in reported LTF, as there is currently no clear 
identifiable outcome within the ART programme to identify this cadre of patient 
(22,23). Incorrect reporting of STF patients as LTF negatively impacts on patient 
continuum of care as financing the ART programme is heavily reliant on retention in 
care figures (30,31). In order for the ART programme to accurately measure 
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retention in care, it is crucial to account for those patients who STF between facilities 
(30). 
Tracing of LTF and Transfer patients: 
Although all efforts to facilitate the ART programmes success are welcomed, little 
focus has been placed on the migratory or transferring population within the context 
of the ART programme; and even less on the silent transfer phenomena (32–34).  
Whilst transferring out of a facility is not considered punitive to the treatment 
programme, LTF is a negative outcome within the ART programme. When a patient 
is identified as LTF, this classification infers that the patient has been ‘lost to care’ at 
their last reporting facility and thus assumed not to be on treatment, or that the 
patient has been ‘lost to care’ at the last reporting facilty, but is in fact on treatment at 
another facilty. Both of these outcomes imply that at some point along the treatment 
continuum, that specific health facility has ‘failed’ to retain that patient in care.  
Multiple studies have been conducted to ascertain mortality figures amongst  
patients identified as LTF (35–38) . Further studies have been undertaken to trace 
patients who have a documented outcome of LTF to ascertain the proportion of 
patients who self-referred or silently transferred (STF) their care to another health 
facility (29,39,40), including three systematic reviews (31,41–43). One study in 
Malawi found that of the 3176 patients identified as LTF, 70% were traced with 56% 
of those traced patients still on ART at another facility with 121 patients having 
silently transferred (30).  
Studies have also sought to trace patients identified as TFO to understand if their 
outcome was a true reflection of status, with one study conducted in Northern Malawi 
having traced 92% of the 805 patients (19% of total cohort) with outcome of TFO 
having actually had arrived as intended at another treatment facility (44). Several 
studies have attributed the reasons for transfer with economic opportunity, family 
responsibility, improved access to care and improved health outcomes or 
decentralization of ART services (28,29,45,46).   
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Migration: 
It is known that the world’s population is on the move with over 214 million people 
having migrated whether that be due to economic opportunities, political unrest, 
internal displacement, environment factors, or human rights abuses (47,48). 
Migration affects the economic, social and health structures of a population, however 
little information is known about the programmatic dynamics and their effect on 
patients who migrate or transfer within the health system and more specifically the 
impact patient migration has on the ART programme (49). Just as global migration 
can destabilize a region, STFs can cause disruption within the ART programme due 
to challenges in correctly identifying patients remaining in care (RIC). In the broader 
context of migration, across-boarder migration refers to movement between 
countries, and internal migration referring to migration within the country boarders. In 
addition, cyclical migration refers to those persons who at one time or another left 
rural homesteads in search of employment (positive migration) only to return to their 
original location due to illness (negative migration) (33,34).  
All cadres of migration have a direct and potentially negative effect on the health 
system, especially in the instances of political upheaval, natural disasters, or disease 
outbreak. Likewise, the phenomenon of patients silently transferring within the ART 
programme due to reasons directly related to the health system, including lack of 
access, poor service, and negative patient experiences have been identified as an 
important area within the ART programme in need of further exploration (31,49,50).  
Within the context of health, various aspects of the health system hinder the ability of 
a patient to easily transfer health facilities, resulting in patients self-referring or 
silently transferring. South African policy that describes the transfer process does not 
exist except in the form of the ART Monitoring and Evaluation Standard Operating 
Procedure [circular 191/2013] (51) and most recently the Western Cape Migration 
Standard Operating Procedure [circular 78/2015] (52). Dissemination of these 
policies to the various levels of health is often sporadic and incomplete or require a 
reinterpretation at source due to lack of resources or understanding (53).  
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Attitudes of health providers and their influence on patient care: 
Communication between patients and HCPs is an essential part of a patients 
treatment success and positive health outcomes (54,55). Explanation by the HCP to 
the patient of how various services within the health system operate, and assurance 
of patients understanding of those services is important in the context of successful 
patient health outcomes (56–59).  This applies to the understanding by the patient of 
the transfer process, as a lack of understanding can impede the transition process 
and lead to potential treatment interruptions or withdrawal from the health service. In 
addition, poor clinical documentation and complicated referral and transfer 
processes all contributes logistical challenges and barriers to the transfer process 
(60,61).  
Gaps or Needs for Further Research: 
Additional studies are needed to gain further insight into the magnitude of STF in 
different ART programme settings and to determine how the STF of patients affects 
the current ART programme in terms of service delivery, monitoring and reporting. 
Investigation into how monitoring systems could be adapted to maintain flexibility 
within the service context must be explored. More research to identify logistical 
challenges, including simplifying referral and transfer procedures that act as as 
barriers to the patient transfer process is needed.  
As the duration of patients on ART continues, studies addressing such areas as 
alternate dispensing methods, work place ART distribution, extending scripting and 
dispensing of ART, and improved operation management of health facilities should 
be further explored.  
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Abstract: 
Patients who Silently Transfer (STF) and who are incorrectly classified as Lost to 
Follow-up (LTF) negatively impact assessment of Retention in Care (RIC) of 
Antiretroviral (ART) programmes. Identifying the proportion of LTF patients who STF 
and the reasons patients STF is a priority in order to ensure patient continuity of 
care, improve policy and treatment guidelines, and provide accurate ART 
programme outcomes. 
A mixed methods approach was adopted using data sourced from an ART 
longitudinal patient monitoring system (eKapa) and patient and healthcare provider 
(HCP) interviews. Adults (≥15 years) on ART with a LTF outcome between 2008 and 
2012 were were traced to determine STF proportions.  
LTF outcome was defined using an established algorithm of ≥ 90 days beyond the 
end of the last prescription. LTF date was the last clinical date that the patients 
attended the facility. STF or ‘Lost’ patients were defined as patients who had a 
reported LTF outcome from one of three identified health facilities, who were 
subsequently ‘found’ as having been registered at another health facility as a New or 
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TFI patient. Thirty patient and five HCP interviews were completed to ascertain 
reasons for STF and understand the clinical management process for transfer 
patients.  
Of the 4166 patients identified as LTF 37% were identified as STF. Sixty-eight 
percent of STFs were female and 52.1% of all STFs were between 25-34 years of 
age. Eighty-four percent of STF patients transferred once. 
Patients were interviewed to ascertain their understanding of the transfer process 
and to identify STF reasons. Although the majority of patients (n=27/30) believed it 
necessary to inform staff of the intent to transfer, more than half suggested 
challenges in requesting a transfer, including fear of negative staff attitudes (n=11), 
emergencies and life events (n=5) and long transfer documentation waiting times 
(n=3).  
HCPs acknowledged patients STF due to challenges with the transferring process 
and fear of repercussions when defaulting treatment. HCPs stated they would not 
prevent patients from requesting a transfer nor turn STF patients away who had 
interrupted treatment or arrived without adequate documentation. The HCPs’ open 
acceptance of transferring patients was inconsistent with patients’ perceptions that 
staff negatively react to patients requesting transfer or those transferring to another 
facility without request. 
Our study showed that incorrect reporting of STF patients negatively affects RIC 
data and RIC in the Khayelitsha ART programme could be underestimated by as 
much as one third. Operational service challenges and staff attitudes contribute to 
STF. Cumbersome transfer documentation processes hinder HCPs’ ability to 
effectively manage an STF. Identifying LTF patients’ that STF and the reasons for 
STF is a priority to ensure continuity of care, improve policy and treatment guidelines 
and provide accurate ART programme outcomes. Adapting current transfer policies 
to facilitate the transfer process for all patients, including those experiencing 
emergencies and life events is essential. Linking electronic patient monitoring 
systems will improve accurate retention in care reporting and improve fluidity of 
transferring of patients between health services. 
63 
 
INTRODUCTION: 
 
Patients who Silently Transfer (STF) and who are incorrectly classified as Lost to 
Follow-up (LTF) negatively impact assessment of Retention in Care (RIC) of 
Antiretroviral (ART) programmes (1,2) and can cause challenges in a healthcare 
providers’ ability to provide a patient with appropriate continuum of care.  
There is global consensus that patients who remain adherent on ART can virally 
supress the disease, reduce the risk of transmission to others, and live their lives 
with minimal interruption to activities of daily living (2–4). 
Patients who STF add to the increase in reported LTF, as there is currently no clear 
identifiable outcome within the ART programme to identify this cadre of patient (3,4). 
Identifying the proportion of LTF patients who STF and the reasons patients STF is a 
priority in order to ensure patient continuity of care, improve policy and treatment 
guidelines, and provide accurate ART programme outcomes.  
Although the treatment guidelines have adapted to the clinical needs of the patients, 
little focus has been place on the development, implementation and management of 
processes and policies for patients transferring between health facilities (5).  
In order for the ART programme to accurately measure retention in care and to 
provide optimal continuous care to patients, it is crucial to account for those patients 
who STF between facilities (2). 
Methods: 
Study Design, Sites and Population: 
We used a mixed methods approach using quantitative and qualitative data. The 
former comprised routine electronic cohort data and the latter consisted of patient 
and healthcare provider interviews from three public ART primary healthcare 
facilities in the health sub-district of Khayelitsha, South Africa. Khayelitsha is the 
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largest township in Cape Town, and home to over 500,000 predominantly Xhosa 
speaking residents of low social economic status (6).  
Quantitative Data: 
Setting and Participants: 
For the quantitative component of the study, the relevant data were sourced from a 
longitudinal electronic patient monitoring system (eKapa) used by all Western Cape 
Provincial primary healthcare (PHC) facilities in the health sub-district of Khayelitsha 
(7). All adults (≥15 years) who ever initiated ART between January 1st 2001 and 
September 30th 2012 at one of three PHC facilities in Khayeltisha, who also had a 
lost to follow-up (LTF) outcome between January 1st 2008 and December 31st 2012 
were included. Due to limitations of the routine data set, all patients identified in the 
data set as having ever initiated at the three CHCs (which was from inception of the 
programme in 2001-2012) were included, and the LTF date parameters were 
selected based on the expansion and support of routine monitoring and evaluation 
systems within the sub-district. The LTF outcome date is defined as the last recorded 
clinical visit based on a predefined algorithm of ≥90 days of drug not in hand (4,8,9). 
Patients were included if they had commenced ART before September 30th 2012, 
and database closure was on or before December 31st 2012 to allow for 3 month 
follow-up for LTF reporting.  
These ‘lost’ patients were then matched using a combination of unnamed, numeric 
identifiers. Patients were considered “found” or having silently transferred (STF) if 
they were identified as having been in care at another facility in the combined data 
set after their recorded LTF outcome date in the original data set.  
Data were extracted from the routine monitoring platform (eKapa) using the Data 
Exchange Standard (DES) extraction method and imported into Excel. 
Data were then matched using probabilistic matching on patient folder number, 
South African ID, name and surname, and date of birth. Once matched, patient 
folder number and names were removed from the patient data set and replaced with 
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a unique study number identifier, the unlinked, anonymised data were then returned 
to the researcher for further analysis.   
Measurements: 
Baseline characteristics for the lost and found patients included demographics (age, 
sex), year of ART initiation and LTF date. Measures of transfer were the number of 
times a patient appeared at another ART facility after the initial LTF date and their 
documented method into ART and prior ART experience, as patient who transfers 
should be captured as Transfer In (Fig. 1). The term transfer-in (TFI) is used in the 
ART monitoring programme to describe a patient who transfers their clinical care 
from one health facility to another. This process (in most instances) requires 
knowledge by the patient’s current facility of their intent to transfer. The process 
includes the current facility clinician providing a written transfer-out (TFO) document, 
which contains key medical information from the transferring facility to the new 
facility.  
 
Fig. 5 Patient classification at time of entry into health facility 
Analysis: 
Baseline characteristics of “found” or STF, and “lost” or non- STF patients were 
described with summary statistics (medians, interquartile ranges, and proportions). 
Mean age was calculated by year of enrolment. Number of times transferred was 
calculated from date of last visit at one facility and subsequent visit date at another 
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facility name. All statistical analysis was performed using Stata 12 (StataCorp, 
Texas). 
Qualitative Data: 
Setting/Participants: 
For the qualitative analysis, 10 ART patients in each of the three PHC facilities in 
Khayelitsha were recruited using convenience sampling techniques. Each facility has 
a registry and waiting area for HIV/ART and TB patients that are separate to the 
general patient population. Patients located in the HIV/ART waiting room in each 
facility were approached for inclusion in the study. Patients were eligible for inclusion 
if they were ≥18 years at one of the three facilities. Patients were recruited for the 
study from each of the facilities’ ART waiting rooms, and each survey took an 
average of 30-40 minutes to complete. HCPs working in the ART services in each of 
the three facilities were selected using convenience sampling. Each facility manager 
at the participating facility was asked by the research for a list of clinicians who were 
working in the service to approach for participation. From that, five HCPs were 
interviewed.  
Procedures: 
The research assistant administered the survey in the patient’s preferred language 
and responses were transcribed and verbally translated during the survey. Both the 
research assistant and lead researcher were present during the survey. This allowed 
for clarity and explanation from the study lead to the research assistant and 
participant during the survey and allowed for further probing of responses where 
incomplete information or misunderstanding occurred.  
HCPs were invited to participate and all efforts were made to conduct the interview 
to prevent any delays of patient consultations. HCPs were interviewed in English as 
the standard language used by the Provincial Department of Health. Using an 
interpretive approach (10), the interview tool, which was a combination of main 
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questions, probing questions and follow-up questions was used to guide the study 
lead during the interview.  
Measures: 
The survey comprised a combination of pre-coded closed and open-ended 
questions. For the closed ended questions, participants were asked each question 
and then provided with the running prompts or responses, and each given response 
was circled. For those questions that had ‘other’ as an option, the researcher 
recorded the responses. Then, during analysis the responses were redefined and 
coded to prevent the response from obtaining a frequency value higher than the 
main codes (10). 
Responses to the patient surveys were translated (and back translated for the Xhosa 
patient interviews) and then both the surveys and interviews were transcribed into 
Microsoft Word, then imported into Atlas.ti, for coding (10). Quantitative survey 
responses were captured into Microsoft Excel, coded and imported into Stata 12 (11) 
(StataCorp, Texas) for analysis.  
Analysis: 
To cover the research questions posed, simple quantitative descriptive statistics 
were calculated from the patients’ interviews. Clinician interviews were analysed 
using the following themes: Reasons for Transfer, Migration, Reasons for STF, and 
HCP and Programmatic Challenges in Managing STF patients. Confidentiality was 
maintained at all times by ensuring no named information was collected. Ethical 
approval for the study was received from the University of Cape Town Human 
Research and Ethics Committee (HREC REF#: 912/2014) and from the Department 
of Health and local health officials.  
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Results: 
Quantitative results: 
This analysis included a cohort of 4166 patients who were identified as LTF between 
January 1st 2008 and December 31st 2012. Of the 4166 patients who were 
considered LTF or “lost” in the cohort, 37% (n=1521) were “found” and therefore 
considered as having silently transferred (STF) to another health facility.  
Table 1 describes the characteristics of the “found” or STF patients. The median age 
at ART start for STF patients was 31 years (IQR 27-36). Women accounted for 68% 
of the total number of silent transfers.  
Eighty-four percent of STF patients transferred once and 13% transferred twice. 
Seventy-two percent of STF patients were incorrectly captured as ‘New’ patients at 
their subsequent facility, and almost all of whom were documented as ‘ART Naïve’. 
Ninety-one percent of STF patients transferred within the Cape Town Metro District, 
three quarters of which were within the Khayelitsha Sub-district.  
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Table 1: Patient Characteristics of Silent Transfer Patients vs Non Silent transfers 
Characteristic Adults (≥15 yrs), N=4166 
 
STF patients 
n=1521 
Non STF patients 
n=2645 
Age at ART Start (yrs), median (IQR) 31 (27-36) 33 (28-40) 
Age Categories, n (%) 
15-24 yrs 227 (15) 258 (10) 
25-34 yrs  792 (52) 1209 (46) 
35-44 yrs  373 (25) 777 (29) 
45+ yrs  129  (9) 401 (15) 
Gender, n (%)   
Women 1027 (68) 1533 (58) 
25-34 yrs  561 (55) 770 (50) 
35-44 yrs  197 (19) 380 (25) 
Men 494 (32) 1112 (42) 
25-34 yrs  231 (47) 439 (39) 
35-44 yrs  176 (36) 397 (36) 
Number of times transferred, n (%)  
Once 1283 (84) 
  
Twice 196 (13) 
  
2-5 times 42 (3) 
  
Location of Silent Transfer within Western Cape Province, n (%)  
Cape Town MDHS** District 1380 (91)   
Khayelitsha Sub-district (within MDHS District) 968 (70)   
Outside of Metro 141 (9)   
Recorded ‘Method into ART’ status at transfer in (TFI) facility*, n (%) 
Incorrectly recorded as ‘New’ at TFI facility 1097 (72)   
Of these patients, incorrectly captured as ‘ART Naïve’, meaning no 
prior ART experience 
1039 (95) 
  
Correctly captured as TFI at transfer facility 424 (28)   
**Metro District Health Service;  
*Programmatic classification used to determine if a patient is new to treatment or has come from another facility. ‘New’ 
implies that a patient has not been on triple therapy before their arrival at ART enrolment facility.  
*Programmatic classification used to determine if a patient is new to treatment or has come from another facility. ‘New’ 
implies that a patient has not been on triple therapy before their arrival at ART enrolment facility. ‘Naïve’ refers to a 
patient never having exposure to ART prior to their first triple therapy ART start date.  
^Patients who were not linked, who may have been true LTF or STF care outside of the Western Cape.  
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Qualitative results: 
Thirty patients were interviewed and of those 90% were on ART with 52% having 
been on ART for more than three years. Of the patients who were interviewed, 70% 
lived within walking distance of the facility where initiated. Five HCPs, including four 
nurses and one doctor were interviewed. Three of the five HCPs had worked in the 
ART service for more than two years.  
In accordance with the study objectives, the following themes were documented and 
are described below. 
Reason for Transfer: 
Of the 30 patients who were asked about their knowledge of the transfer process, 
63% were aware of a formal transfer process. A ‘formal transfer process’ was 
described by patients as providing some form of documentation, usually in the form 
of a transfer letter, to the receiving facilities at time of transfer.  
Several patients associated the lack of following the formality of the transfer process 
with punitive measures from staff, suggesting that if they did not have a letter, they 
would be “shouted at by staff” or not be helped. Those who were not familiar with the 
transfer procedure described that they “had never been told what to do”; with one 
patient suggesting that she did not feel it important to follow formalities.  
Of those patients who classified themselves as an official transfer (n=7), stigma, long 
waiting times and post-natal transfer were reasons for transferring from another 
facility. Five patients stated they transferred to the facility with written transfer 
documentation. Although patient could not determine how well or complete the 
transfer documentation was.   
Patient Fear: 
All patients were asked about the reasons why they would not inform staff of their 
intent to transfer. Patients admitted to fear of negative repercussions from staff in 
requesting transfers. Being fearful of a negative reaction from staff was pervasive 
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among the patients interviewed, for example, one participant remarked, “I’m afraid of 
being shouted at by nurses for all to hear, that would be a barrier for me to ask them 
to leave [transfer]”. Despite this, most stated that they would inform staff of their 
intent to transfer. One nurse was aware of a patient’s fear of repercussions when 
defaulting and said, “The patients are scared of getting into trouble, so they say they 
are new”. Another patient’s reason for not informing the staff of her transfer was her 
fear if she did request a transfer: “I’m afraid of what they will say if I ask to leave. I do 
not want to get into trouble. If you do not follow the rules here, you get into trouble”. 
Negative Patient Experience: 
Eighty-seven percent of patients who were interviewed (n=26) agreed that they 
would be motivated to transfer should they encounter a negative experience at the 
facility, with a patient stating “If I continue to get treated this way, I will go to another 
clinic and I won’t tell them, I will just go”. Negative staff attitudes during the waiting 
period for a clinical visit and during clinical consultations were cited by half of the 
patients as a reason that would trigger a transfer by a patient. “The attitude of the 
nurses is a problem, they say it my fault I’m defaulting. It’s because of my situation. 
Sometimes I sleep without food…Sometimes I have no food so I can’t take the pills 
because I am sick”. 
Patients also cited negative attitudes from clerical staff after a period of treatment 
interruption, “The clerks shout at me each time I came back to the clinic after not 
taking my pills. They get angry with me - there is no priority for disabled people”.  
HCPs (n=5) did acknowledge that their attitude towards patients can contribute to a 
patient’s negative experience at a facility. One nurses expressed how the nursing 
profession must to do more to understand the complexities of patients’ 
circumstances that lead to transfers, defaulting or silently transferring, “We as nurses 
need to change our attitude, we need to embrace the patients, we don’t know their 
story, their problems, so we need to embrace them when they come and not punish 
them by making them wait until the end of the day to be seen, because then they 
won’t come back”. 
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Patients (n=14) cited dissatisfaction with long waiting time between arrival at the 
facility and seeing a clinician. In addition, the lack of information staff provided to 
patients regarding the reason for delays was identified as a frustration for patients, 
with one patient stating “if the clerks could just explain delays. You just watch them 
walking up and down and they don’t inform us of what is taking so long. I just wish 
they would tell us when they are having a problem”.  
This also extended to pharmacy waiting times, with a patient exclaiming “Ooh the 
waiting time, it’s too long, we are waiting everywhere. We are always waiting, 
waiting, waiting….”. Forty-seven percent of patients stated they were unsatisfied with 
the current pharmacy waiting times.   
Stigma:  
Both patients and HCPs identified stigma as reason for transferring. Stigma was 
identified as occurring both in the community and within the facilty. It was linked to 
the use of distinctly separate patient held appointment cards and waiting areas for 
HIV-positive patients, both of which identified them as HIV-infected. Patients and 
HCPs suggested that providing a standardized patient card would facilitate stigma 
reduction within the facility, “Patients go to some clinics and sit in one area and they 
have a green card and others have a white card. They should make it the same for 
all patients”.  
One patient associated stigma with ridicule by staff at a facilty stating, “I changed 
clinics because of stigma at the [other clinic]. I would go to there if they [staff] didn’t 
laugh at me, if they didn’t talk about me, and if it was private”.  
Furthermore, stigma amounted to poor access, with one patient suggesting that he 
accessed ART services outside of his neighbourhood in order to avoid being 
recognized by community members “I travel about 2 hours. I stay in [neighbouring 
town]; I’m too scared for people to know I’m on ARVs. I have to borrow money to 
come to the clinic, R50 each time”. In addition, fear of being identified was especially 
prevalent amongst the younger ARV patients who were more likely to transfer to a 
facility where they were less likely to be identified.  
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Migration: 
Travel between the Eastern and Western Cape was considered a common reason 
for transferring of patients. One HCP explained why patients may not return for their 
appointments, “You have patients who are going to a funeral in the Eastern Cape, 
and you know how things are - there is a celebration one day and there is another 
one and it keeps happening, so patients who don’t intend to be gone for long, stay 
longer and can default treatment and then when they come back they are afraid 
because they have defaulted and don’t want to be shouted at”.  
Another HCP expressed how a patient’s improvement in health due to ARVs might 
cause a patient to transfer, “Patients become more mobile when they feel better. 
They were sick and stayed with a family member or friend and now they are feeling 
better, and they transfer”. 
Family responsibility was also cited by HCPs as a contributing factor for reasons for 
transferring, “Patients need to take care of family in the Eastern Cape, why stay here 
when maybe they have no work and they have an elder family member who needs 
their help? Rather than the uncle sending his pension to help, it’s better for them to 
go back to be with their family-they can then help at home and also not be alone”. 
A patient’s fear of dying alone and the need for family support were frequently 
mentioned by HCPs as reasons for patients transferring; “If they [patients] are sick 
and failing [treatment], they are afraid of death, so they want to go and be close to 
family, they don’t want to die alone”, with several HCPs stating that the fear of death 
by patients is a motivational factor for them returning ‘home’ to be supported by 
family. One HCP explained, “If it’s a patient who transfers here, it’s usually when 
they are very sick and they stay with family here to get well, and then they go back to 
the Eastern Cape”. 
HCPs stated that patients who are very ill return “home to the Eastern Cape to die”, 
so as not to burden the family with the costs associated with transporting a body. 
They also “return home to the Eastern Cape at time of severe illness to be with their 
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families”, in some instances requesting an officially transferring, and in others silently 
transferring.  
Reasons for potential STF: 
Fifty-seven percent of patients cited scenarios that would cause them to STF to 
another facility. Negative staff attitudes (65%) emergencies (29%) and personal 
choice (12%) were most commonly noted.  
HCPs felt that patients who transferred without documentation or who admitted to 
treatment interruption usually did so because of fear of reprisals by informing the 
previous facilities staff of their intent to transfer. “Patients usually transfer when they 
have defaulted or are noncompliant. When they come back having defaulted, they 
are afraid of staff scolding them, so they go to another clinic and say they have never 
been at a clinic before”. 
One patient explained that she returned after three years of having defaulted 
treatment because of a negative staff experience, “I defaulted three years ago 
because I didn’t get the attention I deserved at the clinic so I left. This one day I had 
enough. I dropped my card, and I waited until 4pm. I went to the clerks and asked 
about my folder, but they wouldn’t help me because they were leaving. I went to the 
doctor and he said ‘I’m off duty’ and the nurse said the same thing. So, I wrote on the 
top of my folder ‘I’ll come back when I am sick’, and I never came back. I came back 
after 3 years when I was sick”. This patient also was not aware that a patient could 
transfer to another facility. Both her lack of knowledge of the transfer process and a 
negative clinical experience were reasons she identified as being instrumental in her 
stopping treatment.  
Although patients did speak of negative staff attitudes as a contributory reason for 
STF, 63% were satisfied with their current facility and the interactions with staff, 
although there were some issues expressed concerning staff professionalism. “Here 
at this clinic, when you tell someone about your problems they don’t laugh, when I 
got an STI, I went to [clinic] and I told them about the itching and burning and they 
laughed at me, so I won’t go back there. I just left and came here”.  
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Clinical challenges with managing a transfer patient: 
There were variations amongst HCPs in how they identified a transfer or STF 
patient. Their responses suggest that only patients who arrived with documentation 
are classified as a true transfer. Several HCPs stated that they would only consider a 
patient as an official transfer if the patient provided a completed official transfer 
letter. HCPs voiced their frustrations at the transfer process due to systematic 
challenges, “ooh, the transfer patients, they are very [much more] difficult than the 
new initiations at your clinic. They are difficult because of all the work you have to 
do, to search for information, to phone, to ask so many questions, you spend a lot of 
time running up and down trying to get the information”. 
HCPs were asked what minimum information they required in order to effectively 
manage STF patients. HCPs’ responses were varied including simply accepting a 
patient’s word, or a combination of pill bottles and latest blood results. Most HCPs 
felt that relying on a patient’s word was not sufficient due to their experience of 
patients falsely indicating current ART treatment, “some patients are recurrent 
defaulters - so they transfer from clinic to clinic to get treatment because they don’t 
want people [staff] to know they defaulted. They think we don’t have a way to find 
out, but we can”. HCPs spoke of situations where they had patients who arrived 
stating they had never initiated treatment, “Majority of transfers they have defaulted 
when they come to [this clinic] they say they are new, but they are not”, only to 
discover after clinical and laboratory investigation that the patients had been on 
treatment or had recently defaulted.  
Documentation: 
One clear challenge impeding the ease of the transfer process for HCPs was the 
lack of available transfer documentation provided by patients at time of arrival at the 
facility, “the paperwork – it’s always incomplete - no staging, no results, nothing. We 
get most of the information from the patients themselves”. HCPs said that although 
some patients did arrive with some form of documentation, the incomplete nature of 
the documentation contributed to delays in timeous processing of patients by HCPs, 
“We struggle for days to get the transfer letter. They [patients] know they did wrong 
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by not coming with information. We try to explain that we can’t help you without the 
information”. 
HCPs stated that incomplete blood results and obtaining patient history from 
previous facilities were the main obstacles to the continuum of care process for the 
patient.  
“You phone a clinic and no one answers, it just rings and rings – you just give 
up and take bloods and start from the beginning [work-up patient]” 
“The information is just not there, bloods haven’t been done, no follow-ups 
done or documented correctly” 
Transfer Protective Measures: 
Programmatic and operational interventions implemented by facilities can prevent a 
patient from STF in some instances, “if there is a problem, then I just put it in the 
suggestion box”. In addition, HCPs and patients mentioned that adherence clubs had 
stopped them from STF, with one patient saying that “I wanted to transfer to another 
clinic because of delays and waiting times, but when clubs were introduced, I 
stayed”. 
One HCP stated that introduction of adherence clubs was a positive impact on 
patient treatment and adherence and cited it as a reason for patients transferring to 
to their facility. “Patients transfer here because they know it’s quicker and we have 
clubs, so when they come and they are stable they can go into a club. Patients tell 
us they prefer this clinic to other ones….in the area”. 
Patients were asked what improvements to operational services at the facility they 
would appreciate. Twenty-seven (n=30) suggested a broad range of improvements 
with improving waiting times (70%), addressing negative staff attitudes (41%), and 
increasing the number of staff at facility (37%) being the most cited.  
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In addition, patients cited decreasing the frequency of appointments, increasing 
number of months of medication dispensed, putting measures in place to lessen the 
risk of stigma, and improving facility cleanliness as areas for improvement.  
Likewise, positive healthcare experiences for patients might prevent transfer even in 
cases of relocation and life events. Fifty eight percent of patients said they would not 
change facilities even if relocating, “There is nothing that would make me change, I 
am happy with the clinic”, mostly due to satisfactory service experience at the facility 
where they were enrolled. 
In addition, when asked what reasons would lead a patient to change facilities, four 
respondents said a negative experience at a clinic would not cause them to transfer 
clinics, including one patient who stated ‘I won’t change clinic, even if the nurses 
shout at me, I don’t mind. I like this clinic because I’m getting all my medication at 
this site. 
Discussion: 
In this study of 4166 ART naïve patients who initiated treatment between 2001 and 
2012 and who had a documented outcome of LTF, 37% were found to have silently 
transferred their care to another facility. Incorrect reporting of STF patients as New 
and ART Naive rather than a transfer could over-inflate enrolment figures, with our 
study finding that of those patients who STF’d, 72% were incorrectly captured as 
‘New’ patients at their next facility with over 95% captured as ‘Treatment Naïve’. 
Enrolment figures are based on New patients and do not include TFI patients as a 
TFI patient would have been counted as New at their ART initiation facility. We found 
that operational service challenges at facilities and staff attitudes towards patients 
contribute to STF, with fear of repercussions by HCPs and staff towards patients 
who default treatment contributing to a patient’s decision to STF. Cumbersome and 
complicated transfer procedures and documentation processes hinder a HCPs’ 
ability to effectively manage a STF. 
Almost one third of patients silently transferred to another health facility, these 
findings are in keeping with studies that show that as much as 30% of ART patients 
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Transfer Out of care (12). Evidence suggests that as the threshold of  ART eligibility 
decreases, the number of mobile patients will also increase, thus perpetuating the 
potential of STF (13). 
Current cohort monitoring only follows the clinical outcomes of those patients who 
are initiated as New at one facility to ensure that like is compared with like (14). 
However, seventy-two percent of STF patients were captured at time of transfer as a 
New patients resulting in the potential over estimation of ART initiations in routine 
data. Meaning, when patients on treatment arrive at a subsequent facility they should 
be captured as a  transfer-in (TFI) and will therefore not be included in the cohort 
(15). 
The implementation of a standardized monitoring system for the ART programme, 
allows for greater understanding of patient needs, and data could be more effectively 
used to adapt the treatment and protocol guidelines to improve access and treatment 
(4,16). Omission in the cohort reporting of patients who transfer between facilities 
may not be optimal given the high number of transfer and STF patients. While 
transferring patients are omitted from the routine cohort monitoring system, there is 
increasing recognition by the ART programme that patients who are LTF may have 
silently transferred their care to another health facility (1,17). Hence, improved 
identification and reporting of transfers is crucial for strengthened ART programme 
monitoring. Although the current National 3 tier monitoring strategy for the South 
African ART programme is designed to monitor those patients who transfer-in to a 
facility, the existing infrastructure operational challenges on the ground impede the 
use of this functionality within the programme (4,7,18).  
In the interviews, patients identified poor treatment from staff, family emergencies, 
and the need to travel outside of facility operating times and lack of knowledge of the 
transfer process factors encouraging a STF. 
Importantly, our survey results suggest that while many patients (64%) were aware 
of a formal transfer process, negative staff attitudes would prevent them from 
following procedure. This may suggest that although they said they would inform the 
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staff, a patient’s fear of being reprimanded when requesting a transfer, could trump 
notification, thus contributing to a STF. 
HCPs admitted that they were aware that a potential reason for STF was a patient’s 
fear of repercussions by staff when returning to care after a period of treatment 
interruption and/or having defaulted. Furthermore, they recognized that patients 
might claim to have never been on ART when arriving at a new facility.  
Cost associated with travel to a health facility is a known barrier in accessing ART 
(2,19). Yet the availability and close proximity of 14 ART services within Khayelitsha 
allows for patients to access clinical services within walking distance of their homes, 
eliminating the burden of high transport costs and long travel times when seeking 
healthcare. In the survey, over two-thirds of patients indicated that they were able to 
walk to their clinic – and that the administrative burden of obtaining a transfer letter 
would take longer than the walk to the new clinic. This suggests that Khayelitsha 
itself is well serviced, and that transfer factors may not be directly linked to a lack of 
access but rather to negative patient experiences or fear of healthcare staff. 
Travel between the Western and Eastern Cape is widely practiced, and the health 
system recognizes that patients do migrate between provinces, with service 
providers suggesting that this behaviour is linked to health status and the need to 
family care in the rural home (20).  
The movement of patients between services in the ART programme is recognized 
and acknowledged (21), with patients sometimes requesting official transfers or 
sometimes silently transferring to other health facilities as the current transfer 
procedure is cumbersome, time consuming and often incomplete (22,23). HCPs 
highlighted the complexities of the referral and transfer process as a barrier to their 
ability to easily process a transferring patient, which is in keeping with previously 
literature (24,25).  
At the core of the health system, and an area unable to be easily monitored on a 
macro level is the relationship between the patient and HCP, and how that link 
between patient and provider is key to ensuring successful patient health outcomes 
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(26). The fact that just over 40% of patients did not know about the formal transfer 
process suggests that more patient education by the HCPs on the topic of transfer 
procedures is required.  
Incomplete clinical documentation, poor communication between patients and HCPs, 
and difficulties in patients accessing a facility in order to request official transfer 
documentation, can contribute to the STF of patients. Although South Africa has 
implemented the use of standardized ART clinical stationery, which includes transfer 
letters, non-completion or the inaccurate documentation compounds the challenges 
faced by HCPs in receiving transfer patients (4,27). HCPs identified limited clinical 
consultation time between patient and providers, lack of understanding of how and 
what to document and insufficient stock, all of which negatively affected the ability of 
the staff and HCPs to adequately assess the transferring patient.  
Incorrect or missing information provided by patients when they arrive at the 
receiving facility, further contributes to patient delays as additional clinical 
investigations to determine ART status, is required. 
Strengths and Limitations: 
There were several strengths and weaknesses with the study. The ability to 
triangulate the understanding a STF through the patients and HCP interviews with 
the proportion of STF amongst documented LTF patients was important in gaining 
an understanding of how to adapt the ART programme to the needs of the STF 
patients. 
One limitation of our study was that we did not include patients who could have been 
a LTF and came back into care at the same facility, as these patients’ outcomes 
would have been removed at time of re-entry into care.  
Another limitation was the small number of HCPs who were interviewed, to gain a 
further understanding as to the limitations and challenges facing the HCPs, a larger 
sample size could have been used, however this was not possible given the cost and 
time constraints of the study. Furthermore, interviewing patients who had 
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experienced a silent transfer would have been more effective in understanding 
reasons for STF, the budgetary and time constraints for the study limited the ability 
of the researcher to do this. 
Recommendations: 
Implementing electronic monitoring systems that are networked and that would link 
patient movement between health services is optimal to reduce STF, as well as 
strengthen the ART programme. Implementation of such a system could reduce the 
inaccurate reporting of a transfer patient as LTF and is an important consideration in 
terms of reducing the number of STFs. However, the ability of a developing country 
such as South Africa to implement such a system is difficult given limited 
infrastructure and budgetary constraints.  
Linkage of patients through a networked monitoring and patient management system 
available at each health facility is perhaps the best way in reducing the number of 
incorrectly documented LTFs. Understanding the STF phenomenon will also improve 
the ART programme ability to adequately and appropriately allocate budget and 
resources in order to ensure efficiency within the ART programme. 
Facilitating the transfer process for patients and HCPs by prioritizing the completion 
of patient held card integrated across all health programmes will allow for smoother 
transitions for transfer patients. Including all relevant information on the card, would 
eliminate the need for patients to return to the clinic to request a transfer, thus 
reducing waiting times; provide receiving HCPs with important patient information 
and facilitate the accurate reporting of enrolment figures. 
Interventions focusing on improving waiting times and staff-centred workshops and 
training in order to change attitudes is essential and a key aspect to reducing the 
number of patients who STF their care. Furthermore, interventions to facilitate 
communication between the staff and patients, such as suggestion boxes and staff 
informing patients of expected waiting times could positively contribute to a patient 
staying at one facility.   
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Waiting times can be reduced through the use of dedicated appointment times for 
patients, this should include the provision of appointments for patients who are 
employed. Waiting times can further be improved through efficiencies gained in the 
registries by streamlining tasks and duties for clerical staff through the use of 
electronic patient management systems, integrated registries, and training of clerical 
staff. This could improve the overall patient experience and reduce the number of 
patients who would STF their care to another facility. 
Conclusion: 
Whilst the ART programme continues to facilitate the initiation of HIV patients onto 
ART within the primary healthcare platform, cognisance of ensuring the ongoing 
patient-level monitoring and acknowledging their movement within the programme 
must be taken. This is particularly pertinent in a South African health context, given 
that the HIV epidemic is mature, the challenge to monitor large cohorts of treatment-
experienced patients will only increase. Furthermore, policy makers should ensure 
that operational functionality of the health system does not impede a patient’s desire, 
ability and right to transfer between services (28–31). Our study suggested that 
these processes, where in place were not well understood nor acted on by HCPs 
and patients alike. It is not enough to simply have access to care, but by upholding 
the principles for health provide patient-centric care that is ethical, efficient, 
compassionate, open and transparent, and evidence based, all of which facilitates 
the continuum of patient care. This  is the fundamental right of each individual 
(30,32–34).  
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APPENDIX 1: QUESTIONNAIRE/DATA CAPTURE INSTRUMENT(S) 
Patient survey  
Question Answer Comments 
Short Questions About Medication 
1. Are you taking ARV's? 
a. Yes (0) 
b. No (1) 
c. No answer (2) 
 If No, skip to question 
8. 
2. How long have you been 
taking ARV's? 
a. Less than 6 months (0) 
b. Less than 1 year (1) 
c. Less than 2 years (2) 
d. Less than 3 years (3) 
e. More than 3 years (4) 
f. No answer (5) 
  
3a. Did you initiate ARVs at this 
clinic? 
a. Yes (0) 
b. No (1) 
c. No answer (2) 
If Yes, skip to question 
8  
If No, complete 3b, 3c 
3b. If no, where did you initiate? Facility name (0) 
No answer (1) 
 
3c. Did you transfer from this 
clinic? 
a. Yes (0) 
b. No (1) 
c. No answer (2) 
If no, complete 3d. 
If yes, skip to question 4 
3d. if no, where did you transfer 
from? 
Facility name (0) 
No answer (1) 
 
TRANSFERS ONLY: 
4. Did you transfer with a letter 
a. Yes (0) 
b. No (1) 
c. No answer (2) 
  
5. Did you run out of pills while 
you were transferring from 
one clinic to the other 
a. Yes (0) 
b. No (1) 
c. No answer (2) 
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6. if yes, how long were you 
without pills 
a. 1 day (0) 
b. More than 1 day but less than 1 
week (1) 
c. Greater than one week but less than 
1 month (2) 
d. Greater than one month, but less 
than 3 months (3) 
e. Greater than 3 months (4) 
f. No answer (5) 
 Only answer if YES to 
5 
7. What are the reasons you 
transferred facilities? 
a. Poor clinical care at other facility 
(circled 0/not circled 1) 
b. Rude admin staff at other facility 
(0/1) 
c. Waiting times at other facility (0/1) 
d. Shortage of meds at other facility 
(0/1) 
e. Stigma at other facility (0/1) 
f. Long distance between home/facility 
(other facility) (0/1) 
g. Relocated closer to this clinic (0/1) 
h. Postnatal (0/1) 
i. Other (0/1) 
j. No answer (0/1) 
 
Travel Information 
8. What is the distance from 
where you are staying to this 
clinic? 
a. Less than 5 kms (0) 
b. Between 5 and 10 kms (1) 
c. Between 10 and 20 kms (2) 
d. More than 20 kms (3) 
e. No answer (4) 
  
9. How long does it take you to 
get to this clinic? 
a. Less than 1 hour (0) 
b. Between 1-2 hours (1)  
c. Greater than 2 hours (2) 
d. No answer (3) 
  
10. How do you travel to the 
clinic? 
a. Walk (0) 
b. Taxi (1) 
c. Bus (2) 
d. Drive (3) 
e. Train (4) 
f. No answer (5) 
  
11. How much do you spend to 
get to the clinic? 
a. Between 0-10 rand (0) 
b. Between 10-20 rand (1) 
c. Between 20-30 rand (2) 
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d. Between 30 – 40 rand (3) 
e. Greater than 40 rand (4) 
f. No answer (5) 
Questions about your knowledge and how you have been treated 
12. Have you been told what to 
do if you want to get your 
treatment from another clinic? 
a. Yes (0) 
b. No (1) 
c. No answer (2) 
 If yes, answer 13. 
If no, skip to Q14. 
13. What were you told? 
a. I was told to request a transfer letter 
(0) 
b. Other: (1) 
c. No answer (2) 
  
14. Please indicate how satisfied 
you are with the service you 
received at your clinic 
a. Time you spend before you seeing a 
nurse or a doctor 
1. Satisfied (0) 
2. Somewhat satisfied 
(1) 
3. Somewhat 
dissatisfied (2) 
4. Dissatisfied (3) 
5. No answer (4) 
 b. The way which you are treated at 
this clinic 
1. Satisfied (0) 
2. Somewhat satisfied 
(1) 
3. Somewhat 
dissatisfied (2) 
4. Dissatisfied (3) 
5. No answer (4) 
 c. how the admin clerks treat you 
1. Satisfied (0) 
2. Somewhat satisfied 
(1) 
3. Somewhat 
dissatisfied (2) 
4. Dissatisfied (3) 
5. No answer (4) 
 d. Waiting time at the pharmacy? 
1. Satisfied (0) 
2. Somewhat satisfied 
(1) 
3. Somewhat 
dissatisfied (2) 
4. Dissatisfied (3) 
5. No answer (4) 
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15. Is there anything that you 
would like to see improved at 
the clinics? 
a. Yes (0) 
b. No (1) 
c. No answer (2) 
If no, skip to question 
17 
16. What would you like to see 
improved to improve your 
experience at the clinic? 
(circle as many as needed) 
a. Shorter waiting time/clinic time 
(circled 0/not circled 1) 
b. If staff were more understanding/not 
rude (0/1) 
c. If there were more staff (nurses, 
doctors, pharmacists) (0/1) 
d. If we were supplied with medication 
that will last for longer than a month 
or two (0/1) 
e. Improved facility infrastructure 
(cleanliness, sanitation, better 
condition of building) (0/1) 
f. If appointments were not as frequent 
(0/1) 
g. Other:________________________ 
(0/1) 
h. No answer (0/1) 
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HCP Questionnaire 
Question Answer  Comments Coding Captured (check 
for yes) 
1. Are you a nurse or a 
doctor? 
a. Nurse 
b. Doctor 
   
2. How long have you 
been working in this 
clinic? 
a. Less than 6 months;  
b. 6 months - 2 yrs. 
c. 2-5 yrs. 
d. Greater than 5 yrs. 
   
3. How long have you 
been working in the 
ART services? 
a. 6 months 
b. 6 months - 2 yrs 
c. 2-5 yrs 
d. >5 yrs. 
   
4. In your opinion, on 
average how many 
transfers from other 
clinics do you see on 
a monthly basis? 
Open Ended Response:     
5. In your opinion, what 
proportion of patients 
that you see who are 
transfers, transfer in 
having defaulted 
treatment? 
    
6. Do most transfers 
come with written 
documentation? 
a. YES 
b. NO 
c. other:_______________ 
   
7. If yes, what form of 
documentation do 
they come with 
a. TFO letter 
b. green card 
c. paper 
d. other:  
   
8. In your experience, 
what proportion of 
transfers come with 
documentation/withou
t documentation 
Open Ended Response:     
9. How do you assess 
transfers who arrive 
without 
documentation? 
a. Clinically;    
b. Administratively:    
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10. As a health provider, 
what do you require to 
continue a transfer 
patient without 
documentation: what 
are your minimum 
requirements? 
a. TFO letter 
b. Green card 
c. Paper 
d. Pill bottles 
e. other: 
   
11. Why do you think 
patients transfer? 
a. rude health providers    
b. rude reception staff    
c. long waiting times    
d. drug stock out    
e. Stigma    
f. Long distance to travel    
g. Change of Address    
h. Employment 
change/opportunity 
   
12. Why do you think 
patients move 
between clinics 
without informing 
anyone? 
a. Waiting time for TFO letter    
b. They don’t know the process    
c. Being scolded by registry staff    
d. Being scolded by health 
providers 
   
e. Waiting times for transfer 
documentation 
   
f. fear of not being accepted at 
new facility 
   
13. Do you think that we 
should try to limit 
transfers? 
a. Yes  
b. No  
   
14. If yes, in what way? Open Ended Response:     
15. Who would you allow 
to transfer? 
a. TB/HIV co-infected patients 1. Yes 
2. No 
  
b. foreign nationals 1. Yes 
2. No 
  
c. pregnant women 1. Yes 
2. No 
  
d. patients with comorbidities 1. Yes 
2. No 
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e. failing patients  1. Yes 
2. No 
  
f. repeat defaulters 1. Yes 
2. No 
  
g. treatment duration:  1. patients 
on 
<3mths 
tx; 
2. patients 
on > 
3mths tx  
3. <6 mths 
tx;  
4. 1 year;  
5. > 1 year 
  
16. Do you find that 
managing a transfer 
patient more difficult 
than initiating and 
following up patients? 
Open Ended Response:     
17. What programmatic or 
policy changes would 
you like to see 
regarding the 
management of 
transfer patients? 
Open Ended Response:     
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APPENDIX 2: CONSENT FORMS AND PARTICIPANT INFORMATION FORM 
University of Cape Town Information Sheet and Consent Form – PATIENT SURVEY 
FROM LOST TO FOUND: THE SILENT TRANSFER OF PATIENTS ON 
ANTIRETROVIRAL THERAPY IN KHAYELITSHA, SOUTH AFRICA 
What is the University of Cape Town and what is this research about? 
The University of Cape Town is a tertiary educational organisation based in Cape 
Town, Western Cape. The Centre for Infectious Diseases, Epidemiology, and 
Research is one centre within the School of Public Health at the University of Cape 
Town that conducts research that focuses on HIV/TB, health system strengthening 
and other health related topics. All research at the University of Cape Town has to 
be approved before it begins by the Human Research Ethics Committee. This is a 
registered human ethics committee, whose purpose is to make sure that the 
research is important, that all ethical policies and procedures are adhered to and that 
participants’ safety and rights are respected. 
In this research, we want to learn more about your thoughts on your experiences at 
this health facility and also on reasons for potential reasons on why you would 
transfer your healthcare from one health facility to another. We would like to ask 30 
participants like yourself who are attending one of the 3 CHC clinics in Khayelitsha to 
complete a survey.  
Why do you want to talk to me and what does it involve? 
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We have selected you to ask you to complete a survey about your experiences at 
this healthcare facility and understand what some of the potential reasons for 
transferring to another site would be. 
We feel that your experience as a person who attends this clinic you can contribute 
much to our understanding and knowledge of why patients silently transfer their care 
between health services. 
My colleague will provide you with a survey consisting of questions about your 
experiences at this current facility and what some of the reasons would be to cause 
you to move to another facility. If you do not want to answer any of the questions you 
may leave the question blank and move on to the next question. My colleague will be 
on hand should you need clarity on the questions. You will have the choice to 
complete the survey in either English or Xhosa. No-one else but the interviewer will 
be present unless you would like someone else there  
The survey should take approximately 20-30 minutes to complete.  
Are there any risks or disadvantages to me for taking part?  
You may find that giving information regarding your healthcare experience difficult or 
uncomfortable. You may feel that disclosing information regarding your healthcare 
experience could have a negative impact on the clinical care you receive. There will 
be no negative impact on the care you receive if you consent to this research. 
Furthermore, you will not forfeit your appointment should you agree to participate 
and there will not be any delay in your treatment. The results of this study will be 
presented without mention of any personal information or facility names. No results 
will be able to be linked back to a specific person or facility.  
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The study methods, results, and discussion will be compiled into a journal article, a 
shorter summary, as well as a presentation in order to achieve maximum benefit 
from the research. You will also receive a copy by hand or e-mail before submission 
to a journal. If you do not agree with any part of the analysis, you must please inform 
the principal researcher, whose contact details are below.  
Are there any benefits to me for taking part? 
There are no individual benefits to taking part, but in answering our questions you 
will help us improve our understanding of transferring patients and any potential 
barriers in the health system facing silent transfers and patients reasons for silently 
transferring.  
Who will have access to the information I give? 
We will not share individual information about you or other participants with anyone 
beyond a few people who are closely concerned with the research. All of our 
documents are stored securely in locked cabinets and on password-protected 
computers.  
The knowledge gained from this research will be shared in summary form, without 
revealing individuals’ identities.  
What will happen if I refuse to participate?  
All participation in research is voluntary.  You are free to decide if you want to take 
part or not.  If you do agree you can change your mind at any time without any 
consequences.   
What if I have any questions? 
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You are free to ask me any question about this research. If you have any further 
questions about the study, you are free to contact the research team using the 
contacts below:  
PI’s name(s) and contacts: 
Dr. Kathryn Stinson (Epidemiologist)/Ms. Claudine Hennessey (Professional Nurse) 
University of Cape Town 
School of Public Health and Family Medicine 
Centre for Infectious Diseases, Epidemiology and Research 
Falmouth Building, Level 5 
Observatory, Cape Town 
Phone: 021-406-6760 
If you want to ask someone independent anything about this research, please 
contact 
The committee giving ethical approval for this study is the Human Research Ethics 
Committee Faculty of Health Sciences, University of Cape Town. If you have any 
problems or questions about this study, please contact the Ethics committee directly, 
at telephone number: 021 406 6338 
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CONSENT FORM – PATIENT SURVEY 
FROM LOST TO FOUND: THE SILENT TRANSFER OF PATIENTS ON 
ANTIRETROVIRAL THERAPY IN KHAYELITSHA, SOUTH AFRICA 
I have had the study explained to me. I have understood all that has been read and 
had my questions answered satisfactorily  
  Yes,  please tick I agree to participate 
I understand that I can change my mind at any stage and it will not affect me/my 
child in any way. 
Signature:  
 
Date
: 
 
  
Participant Name:  Date:  
 (please print name)  
I certify that I have followed the study SOP to obtain consent from the participant. 
S/he apparently understood the nature and the purpose of the study and consents to 
the participation in the study. S/he has been given opportunity to ask questions 
which have been answered satisfactorily. 
Signature:         Date
: 
 
  
Designee/investigator’s 
name name  Name: 
 Time:  
Name (please print name)  
Thumbprint of patient as named above if they cannot write: 
______________________ 
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Participants’ FAQs and Some Answers 
What is a research study? 
A research study is a very careful way of looking at something and collecting 
information about what is being looked at. It can be as simple as asking a few 
questions such as in a survey or in an interview. Or it can be more difficult and may 
look at a particular sickness or testing new treatments for a particular sickness. 
What is a research participant? 
A research participant is a person who agrees to take part in a research study. This 
is completely voluntary. As a research participant you will be helping the researcher 
to answer the questions in the study. You can decide you no longer want to be in the 
study at any time. 
What is a protocol? 
A research protocols helps a researcher to carry out the research. A protocol is like a 
cookbook. It tells the researcher what can and cannot happen during the research. It 
includes information the researcher must follow to protect participants from harm. 
This protocol must be reviewed by a Human Research Ethics Committee before the 
research can begin. 
Can anyone be in a research study? 
Each study has a list of who can and cannot be in the research. This is written in the 
protocol. In order to protect research participants, only people who qualify can be in 
a study. 
What is a principal investigator? 
The principal investigator or PI is the person who is in charge of the research study. 
The PI has to make sure that everything is done properly. There may also be other 
people who help with the research study. There may be people who help to translate 
the questions into a participant’s home language, there may be people who ask for 
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informed consent and people who make sure that participants’ personal information 
is kept confidential. 
What is a Human Research Ethics Committee? 
The Human Research Ethics Committee is a group of people such as doctors, 
scientists, dieticians, physiotherapists and some community people. This Committee 
must look at every protocol before a research study can begin and it watches what 
happens during a study. This is to protect participants and to make sure that 
researchers keep any risks as low as possible. 
What is informed consent? 
If you decide you would like to be in a research study, the facts about the research 
will be given to you in an information sheet or consent form. This is to help you 
understand what will happen to you in the research study. It will explain the kinds of 
things that you can expect will happen at each visit so that you can make up your 
mind. You will be told about all the risks, if there are any benefits and any other 
options to the study. You will be able to ask any questions about the study and you 
may be able to speak to your family or friends before making your decision. You are 
also able to ask questions during the study. 
Investigators 
Investigators should ask questions to make sure potential participants understand 
what they are consenting to. 
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Healthcare Provider Information Sheet and Consent Form 
FROM LOST TO FOUND: THE SILENT TRANSFER OF PATIENT ON 
ANTIRETROVIRAL TREATMENT IN KHAYELITSHA, SOUTH AFRICA 
What is the University of Cape Town and what is this research about? 
The University of Cape Town is a tertiary educational organisation based in Cape 
Town, Western Cape. The Centre for Infectious Diseases, Epidemiology and 
Research is one centre within the School of Public Health at the University of Cape 
Town that conducts research that focuses on HIV/TB, health system strengthening 
and other health related topics. All research at the University of Cape Town has to 
be approved before it begins by the Human Research Ethics Committee. This is a 
registered human ethics committee, whose purpose is to make sure that the 
research is important, that all ethical policies and procedures are adhered to and that 
participants’ safety and rights are respected. 
In this research, we want to learn more about your on why patients transfer their 
healthcare from one health facility to another and your thoughts on the management 
of such patients. We would like to ask about 6 participants like yourself who are 
working in one of the 3 CHC clinics in Khayelitsha to complete in-depth, semi 
structured interview.  
Why do you want to talk to me and what does it involve? 
We have selected you to ask you participate in an in-depth, semi structured interview 
in order to understand your perceptions of patients who transfer between health 
facilities and how you manage the treatment of such a cadre of patients. 
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We feel that your experience as a clinician working at this facility you can contribute 
much to our understanding and knowledge of why patients silently transfer their care 
between health services and how that impacts on your job as a clinician. 
I/My colleague will provide you with a set of questions about the silent transfer 
patients. If you do not want to answer any of the questions you may ask to move 
onto the next question. I/My colleague will be on hand should you need clarity on the 
questions asked. The questions will be asked in English. No-one else but the 
interviewer will be present unless you would like someone else there  
The survey should take approximately 30-40 minutes to complete.  
Are there any risks or disadvantages to me for taking part?  
You may find that giving information regarding your healthcare experience difficult or 
uncomfortable. You may find that giving information regarding your job sensitive and 
uncomfortable. You may feel that disclosing information regarding your practice of 
managing transfer patients could get you into trouble or have an impact on your 
performance review or staff relations. The results of this study will be presented 
without mention of any personal information or facility names. No results will be able 
to be linked back to a specific person or facility.  
The study methods, results and discussion will be compiled into a journal article, a 
shorter summary as well as a presentation in order to achieve maximum benefit from 
the research. You will also receive a copy by hand or e-mail before submission to a 
journal. If you do not agree with any part of the analysis, you must please inform the 
principal researcher, whose contact details are below.  
Are there any benefits to me for taking part? 
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There are no individual benefits to taking part, but in answering our questions you 
will help us improve our understanding of transferring patients and any potential 
barriers in the health system facing silent transfers and patients reasons for silently 
transferring.  
Who will have access to the information I give? 
We will not share individual information about you or other participants with anyone 
beyond a few people who are closely concerned with the research. All of our 
documents are stored securely in locked cabinets and on password-protected 
computers.  
The knowledge gained from this research will be shared in summary form, without 
revealing individuals’ identities.  
What will happen if I refuse to participate?  
All participation in research is voluntary. You are free to decide if you want to take 
part or not. If you do agree you can change your mind at any time without any 
consequences. 
What if I have any questions? 
You are free to ask me any question about this research. If you have any further 
questions about the study, you are free to contact the research team using the 
contacts below:  
PI’s name(s) and contacts: 
Dr. Kathryn Stinson/Ms. Claudine Hennessey (Professional Nurse) 
University of Cape Town 
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School of Public Health and Family Medicine, Centre for Infectious Diseases, Epidemiology and 
Research 
Falmouth Building, Level 5 
Observatory, Cape Town 
Phone: 021-406-6760 
If you want to ask someone independent anything about this research, please 
contact 
The committee giving ethical approval for this study is the Human Research Ethics 
Committee Faculty of Health Sciences, University of Cape Town. If you have any 
problems or questions about this study, please contact the Ethics committee directly, 
at telephone number: 021 406 6338 
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CONSENT FORM – Healthcare Provider 
FROM LOST TO FOUND: THE SILENT TRANSFER OF PATIENTS ON 
ANTIRETROVIRAL THERAPY IN KHAYELITSHA, SOUTH AFRICA 
I have had the study explained to me. I have understood all that has been read and 
had my questions answered satisfactorily  
  Yes, please tick I agree to be interviewed 
I understand that I can change my mind at any stage and it will not affect me in any 
way. 
Signature:  
 
Date
: 
 
  
Participant Name:  Date:  
 (please print name)  
I certify that I have followed the study SOP to obtain consent from the participant. 
S/he apparently understood the nature and the purpose of the study and consents to 
the participation in the study. S/he has been given opportunity to ask questions 
which have been answered satisfactorily. 
Signature:         Date
: 
 
  
Designee/investigator’s 
name name  Name: 
 Time:  
Name (please print name)  
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Participants’ FAQs and Some Answers 
What is a research study? 
A research study is a very careful way of looking at something and collecting 
information about what is being looked at. It can be as simple as asking a few 
questions such as in a survey or in an interview. Or it can be more difficult and may 
look at a particular sickness or testing new treatments for a particular sickness. 
What is a research participant? 
A research participant is a person who agrees to take part in a research study. This 
is completely voluntary. As a research participant you will be helping the researcher 
to answer the questions in the study. You can decide you no longer want to be in the 
study at any time. 
What is a protocol? 
A research protocols helps a researcher to carry-out the research. A protocol is like a 
cookbook. It tells the researcher what can and cannot happen during the research. It 
includes information the researcher must follow to protect participants from harm. 
This protocol must be reviewed by a Human Research Ethics Committee before the 
research can begin. 
Can anyone be in a research study? 
Each study has a list of who can and cannot be in the research. This is written in the 
protocol. In order to protect research participants, only people who qualify can be in 
a study. 
What is a principal investigator? 
The principal investigator or PI is the person who is in charge of the research study. 
The PI has to make sure that everything is done properly. There may also be other 
people who help with the research study. There may be people who help to translate 
the questions into a participant’s home language, there may be people who ask for 
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informed consent and people who make sure that participants’ personal information 
is kept confidential. 
What is a Human Research Ethics Committee? 
The Human Research Ethics Committee is a group of people such as doctors, 
scientists, dieticians, physiotherapists and some community people. This Committee 
must look at every protocol before a research study can begin and it watches what 
happens during a study. This is to protect participants and to make sure that 
researchers keep any risks as low as possible. 
What is informed consent? 
If you decide you would like to be in a research study, the facts about the research 
will be given to you in an information sheet or consent form. This is to help you 
understand what will happen to you in the research study. It will explain the kinds of 
things that you can expect will happen at each visit so that you can make up your 
mind. You will be told about all the risks, if there are any benefits and any other 
options to the study. You will be able to ask any questions about the study and you 
may be able to speak to your family or friends before making your decision. You are 
also able to ask questions during the study. 
Investigators 
Investigators should ask questions to make sure potential participants understand 
what they are consenting to 
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APPENDIX 3: LETTER OF APPROVAL FROM RESEARCH ETHICS COMMITTEE 
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APPENDIX 4: INSTRUCTIONS FOR AUTHOR OF JOURNAL WHOSE FORMAT HAS 
BEEN USED 
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